doi: 10.3390/ijms20205064 200 ChangYFZhangDHuWMLiuDXLiL
Brief Introduction and Physiological Function of Glucagon Like Peptide-1 Receptor Agonists Glucagon like peptide-1 (GLP-1) is the second incretin identified in 1983
At a tolerated treatment stage: nausea may decrease, although persistent symptoms require review
In the muscle atrophy mouse model, Ex-4 also increased muscle mass and muscle fiber size and improved muscle function
A few mechanisms that don't reduce neatly to mesolimbic dopamine: (1) conditioned aversion, GLP-1 activation engages nausea/malaise circuits, so some of the reduction in substance use may reflect aversive conditioning rather than reward modulation per se
3,4 This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases